Arrowhead Pharmaceuticals · 1 day ago
Associate Manufacturing Scientist I
Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs that treat intractable diseases through RNA interference. The Associate Manufacturing Scientist I will assist in the synthesis and purification of large scale oligonucleotides while ensuring compliance with GLP/GMP protocols and maintaining accurate documentation.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Follow batch records, SOPs, and work instructions to detail
Document all operations in batch records and logbooks
Comply with GMP protocols
Operate large scale oligonucleotide manufacturing equipment (i.e. oligonucleotide synthesizer, purification skid, tangential flow filtration system, lyophilizer, ChemGlass reactors, pH/conductivity meters, peristaltic pumps, etc.)
Assist other chemists within the Manufacturing group during synthesis and purification of oligonucleotides including:
Reagent solution preparation
Mobile phase preparation
Column Packing
Fraction collection
Perform oligonucleotide/intermediate analysis via LCMS
Communicate with cross-functional groups such as Process Development, Analytical Development, Quality Control, Quality Assurance, etc
Maintain a clean work space
Maintain safety by wearing required personal protective equipment
Track and update raw material usage in D365 ERP software
Act as production campaign lead
Assist with new personnel training
Qualification
Required
Bachelor's degree in a scientific field OR appropriate work experience
Entry level to 2 years experience in a similar position
Good verbal and written communication skills
Ability to work in a team environment
Ability to pay attention to detail
Preferred
Experience working in a GMP setting and controlled documentation
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Recent News
2026-01-08
2026-01-07
Company data provided by crunchbase